Reyvow (Lasmiditan Succinate) Patent Expiration, LOE Window & CMS Spending

Reyvow (Lasmiditan Succinate) by Eli Lilly: FDA Orange Book core substance LOE 2037-12-05 (last listed 2040-07-06), 0 AB generics, $14.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEli Lilly
FDA Application & PathwayN211280 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2037-12-05
Last Listed Patent or Exclusivity Date2040-07-06
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$14.3M
2024 Medicare Part D Spend$9.8M
2024 Medicaid Spend$4.5M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.